PMV Pharmaceuticals(US:PMVP) Globenewswire·2025-11-12 13:00Core Insights - PMV Pharmaceuticals reported financial results for Q3 2025, highlighting advancements in their clinical study and financial position [1][2] Financial Performance - As of September 30, 2025, PMV Pharma had $129.3 million in cash, cash equivalents, and marketable securities, down from $148.3 million as of June 30, 2025 [3][4] - The net loss for Q3 2025 was $21.1 million, an increase from $19.2 million in Q3 2024, primarily due to higher research and development costs [10][14] - Research and development expenses for Q3 2025 were $18.2 million, compared to $16.9 million in Q3 2024 [10][14] - General and administrative expenses decreased to $4.3 million in Q3 2025 from $4.9 million in Q3 2024 [10] Clinical Developments - The PYNNACLE study, evaluating rezatapopt, showed a 34% overall response rate among 103 evaluable patients, with a median duration of response of 7.6 months [4][5] - In the ovarian cancer cohort, the overall response rate was 46% among 48 evaluable patients, with a median duration of response of 8.0 months [4][5] - The company plans to submit a New Drug Application (NDA) for rezatapopt in the first quarter of 2027 for the treatment of platinum-resistant/refractory ovarian cancer [2][4] Company Overview - PMV Pharmaceuticals focuses on precision oncology, specifically targeting p53 mutations, which are present in approximately half of all cancers [8] - The company was co-founded by Dr. Arnold Levine, a pioneer in p53 biology [8]